Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1.
about
Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathologic myopiaLaser photocoagulation for choroidal neovascularisation in pathologic myopiaProfile of verteporfin and its potential for the treatment of central serous chorioretinopathyMyopic choroidal neovascularisation: current concepts and update on clinical managementAnti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical applicationIs reduction in the risk of vision loss the only benefit of photodynamic therapy in predominantly classic subfoveal choroidal neovascularization?Verteporfin for age-related macular degeneration.Photodynamic therapy using verteporfin in circumscribed choroidal haemangioma.Angiographic features after photodynamic therapy for choroidal neovascularisation in age related macular degeneration and pathological myopia.Outcomes in verteporfin photodynamic therapy for choroidal neovascularisation--'beyond the TAP study'.Clinical pharmacokinetics of verteporfin.Confocal scanning laser tomography analysis of choroidal neovascularization and correlation with quantitative fluorescein angiography.Comparison of 1-year therapeutic effect of ranibizumab and bevacizumab for myopic choroidal neovascularization: a retrospective, multicenter, comparative studyIndocyanine green angiographic features of myopic subfoveal choroidal neovascularization as a prognostic factor after photodynamic therapy.Recent trends in the management of maculopathy secondary to pathological myopia.Neuroprotective response after photodynamic therapy: role of vascular endothelial growth factorRanibizumab, verteporfin photodynamic therapy or observation for the treatment of myopic choroidal neovascularization: cost effectiveness in the UK.Choroidal neovascularization following laser in situ keratomileusis for high myopia: a case series.Interventions for Age-Related Macular Degeneration: Are Practice Guidelines Based on Systematic Reviews?Comparison of foveal-sparing with foveal-involving photodynamic therapy for myopic choroidal neovascularization.Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial.A systematic review and meta-analysis comparing intravitreal ranibizumab with bevacizumab for the treatment of myopic choroidal neovascularisation.Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab.Predictive factors for visual outcome to intravitreal bevacizumab in young Chinese patients with myopic choroidal neovascularizationCurrent and emerging treatment options for myopic choroidal neovascularizationVerteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation.Subretinal fibrosis after photodynamic therapy in subfoveal choroidal neovascularisation in highly myopic eyes.Visual hallucinations and Charles Bonnet syndrome after photodynamic therapy for age related macular degeneration.Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up.Correlation of optical coherence tomography, with or without additional colour fundus photography, with stereo fundus fluorescein angiography in diagnosing choroidal neovascular membranesPhotodynamic therapy with verteporfin for chronic central serous choroidoretinopathy and idiopathic choroidal neovascularization-first report from the sultanate of omanOptical coherence tomography to monitor photodynamic therapy in pathological myopiaDifferent transitions of multifocal electroretinogram recordings between patients with age-related macular degeneration and polypoidal choroidal vasculopathy after photodynamic therapy.Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopiaCombined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study.Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia.The 12-month outcome of three consecutive monthly intravitreal injections of ranibizumab for myopic choroidal neovascularization.Photodynamic therapy: current role in the treatment of chorioretinal conditionsComparison of photodynamic therapy, ranibizumab/bevacizumab or combination in the treatment of myopic choroidal neovascularisation: a 9-year-study from a single centre.Effect of Factor XIII-A G185T Polymorphism on Visual Prognosis after Photodynamic Therapy for Neovascular Macular Degeneration
P2860
Q24194332-BCE2558C-86FC-4AEB-B1E7-16DAFBEAD92DQ24245460-3D2CCFF5-7133-4712-92A3-A7791D2D3B3FQ26824756-ABCF4A3E-0B42-4114-802F-F28FE75E0A07Q26865884-6996FC2C-3940-4DE5-8739-776A0384ABAAQ28082140-00756DCA-4967-460D-BF21-D91AD38C0CAAQ30438969-7FC78278-8A4D-4F62-AADD-FC388590DEEAQ30798252-A96EB1A0-C05B-4A5C-BC5B-4B532865C907Q30875336-027A2900-73C6-4FC4-9B94-1025ECC77152Q30883131-1E516B42-8CDE-4349-9328-86A2A6FA80BCQ31047729-04283FA1-71FE-4C20-9EB9-D8F94DAF105AQ31058006-B16331AC-3AEA-41AC-A039-6A31DA017D8CQ33431311-7200FB26-EC76-4157-98B4-3801629DB8C8Q33701661-1621BAEA-0B40-49C8-B286-630A8B98195EQ34014880-0E9B33C0-8318-40F7-9C39-0C09DA44515AQ34096895-6435FF5B-1449-42F7-BD4A-859F769371ACQ34101883-E14544AC-5F5F-4159-B4D6-B028F0DA4A3EQ34410824-E7B5AC3E-0422-411A-BEE8-9D6841995415Q34449974-01D44F15-82EA-41BB-85B7-FC80A1707D85Q34510579-FA5C21F1-6E4F-48C5-BD94-BC69EEAFD8BEQ34992533-17620EF8-87AF-489C-9D5C-F4898F3A435BQ35319079-F7C05ABE-7FA5-4867-9DEA-40F3C2393E51Q35436686-4545C059-2CF8-4C3F-9C88-DD5449A2E19CQ35443684-B3A0CB1C-5B55-4584-BC8C-034FB5A456B9Q35467637-4C9CBDFC-CFE6-44D3-984A-93E8F7FD2793Q35576259-F3DFF7CD-40DD-4E29-B8B5-2A571DBB5F28Q35590475-34689B67-A980-4D0C-B9AA-565C15B50F79Q35591157-FF8892B8-41C2-4211-B55D-BB6C6BBFA482Q35591263-E43BED3B-A3BE-4EB6-BFF9-F45154E0819AQ35592511-4F19AA1C-F067-4142-BC61-99597896CA26Q35593554-4C89FFC6-EFE3-4BC8-9236-9975F5996D1BQ35740839-9FE93726-5F76-492F-B710-B6FD90151800Q35761749-6137AC41-249A-4F4E-BA0B-B26B836234BFQ35762763-B3D6E47E-A8E9-4B59-AA63-DFC602C9726EQ35762959-D015AA98-9AB5-42BF-926C-F80698D3972CQ35763017-AA10456D-D97D-46A4-8951-2BA1F31E7E04Q35763028-2DC9CD2D-C0E0-41CA-AA65-1AB833BD537CQ35860198-F750F465-155C-4DCA-BECD-7B1E124674A9Q35888341-6BCC117D-3CA8-4F97-AE9D-399CB2444436Q35899756-88CADBCF-EF64-4864-9ABB-758A3C2BEB90Q36088747-0E98E691-E824-41FB-B6B1-BBD9D4BB7EC7
P2860
Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Photodynamic therapy of subfov ...... nical trial--VIP report no. 1.
@ast
Photodynamic therapy of subfov ...... nical trial--VIP report no. 1.
@en
type
label
Photodynamic therapy of subfov ...... nical trial--VIP report no. 1.
@ast
Photodynamic therapy of subfov ...... nical trial--VIP report no. 1.
@en
prefLabel
Photodynamic therapy of subfov ...... nical trial--VIP report no. 1.
@ast
Photodynamic therapy of subfov ...... nical trial--VIP report no. 1.
@en
P1433
P1476
Photodynamic therapy of subfov ...... nical trial--VIP report no. 1.
@en
P2093
Verteporfin in Photodynamic Therapy Study Group
P304
P356
10.1016/S0161-6420(01)00544-9
P577
2001-05-01T00:00:00Z